home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  September 22, 2021
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 465 active entries

Replicor Inc.

6100, avenue Royalmount
Montreal, QC, H4P 2R2

Phone: 514-496-9011
Fax: 514-496-9021
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it


Replicor is developing a new drug that will revolutionize the

treatment of patients with chronic hepatitis B which

affects up to 350 million patients worldwide. By blocking the release of a

viral protein called HBsAg, our drug allows the re-establishment of a

proper immune response to the infection and results in a high proportion of

patients achieving long term immunological control over their infection.


The efficacy and safety of our drug has already been successfully

demonstrated in a randomized phase II human clinical trial. Based on

Replicor's current clinical trial results, it is projected that a functional

control rate of 80% will be achieved when our drug is used in combination

with currently available approved drugs. The most effective treatment to

date can only achieve a rate of functional control less than 10 %.


Co-infection with hepatitis B and hepatitis D affects 15-20 million patients

worldwide and is the most aggressive form of viral hepatitis leading to a

high rate of cirrhosis. No drug has been approved for this condition making 

this an orphan drug indication with the possibility of accelerated approval

by the FDA and EMA. We have demonstrated in a recent proof of concept

clinical trial published in The Lancet Gastroenterology & Hepatology, that

7 patients out of 11 have completely eliminated the HDV virus from their

blood when receiving our drug in combination with Pegasys making our

drug the most promising asset in this field.

Longer treatment durations are expected to achieve higher rates of cure for this condition.








Selected Categories:
Product Company   Service Company
- Research
- Research
- Research

Last update of this entry: March 03, 2020

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.